SBIR/STTR Research Award

Reagents specific for all N-glycans

Award identifier dbc80a01d1472e699a114673bab04179abdc2070b8c71faf97b9ecfcd45b2ca8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$504,888

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
LECTENZ BIO, INC.
Proposal award date
2017-08-01
Contract end date
2020-07-31
UEI
JTGCK219C6F4
Solicitation number
PA19-029
Topic code
400

Research abstract

PROJECT SUMMARY Glycans have several distinct properties that make them excellent targets for disease biomarkersFirstlytheir location glycans on cell surfaces makes them the first point of contact for cellular interactionsand thus they are crucial in the control of normal metabolic processesSecondlycell surface molecules are also strategically exposed for surveillance by the immune system allowing for the potential of immune recognition of abnormal cellsThirdlyspecific glycan structures that are not presentor are in low amountsin normal states proliferate in disease statessuch as cancerAnd lastlychanges in glycosylation involve many proteinsincluding those that are highly abundantThereforea single change in a cellandapos s glycosylation machinery can affect many different glycoconjugatesTo effectively employ and discover glycan disease markers a wide range of highly specific reagents are urgently neededUsing structurally guided directed evolutionwe will convert the newly identified PNGase F II carbohydrateprocessing enzyme into a pan specific high affinity reagent for peptides and proteins that contain asparaginelinkedN linkedcarbohydrate chainsSuch engineered lectin like reagents derived from enzymes are calledLectenzand have several advantages over lectins and antibodiesThe advantages of Lectenzinclude precise definition of specificityease of recombinant expressionandfor human enzyme homologuesminimal in vivo toxicityenabling their potential use as imaging reagentsA pan specific N glycan Lectenzderived from PNGase F II would directly address the needs of glyco biomarker detection in mass spectrometry based glycomics proteomics analysis by enabling sample enrichmentGlycopeptide sample enrichment aids glycosylation site mapping by eliminating non glycosylated peptideswhich would otherwise lower the signals from glycopeptides that have low ionization efficiencyGlycosylation site mapping is essential in fully characterizing and exploiting glycans as markers of specific disease statesand yet no current reagents exist that can be used to enrich a sample in all constituent N linked glycansThe principle advantages of an engineered Lectenzover an antibody are that the Lectenzis specific to the carbohydrate sequencebutin contrast to antibodieswill recognize that sequence in a broad range of glycansFurtherin contrast to carbohydrate reagents based on plant lectinsengineered Lectenzare derived from enzymes that have exquisite substrate specificities and low toxicities PROJECT NARRATIVE Using structurally guided genetic manipulations we will convert the carbohydrate processing enzyme PNGase F II into a pan specific N glycan affinity reagentcalled a Lectenzfor the detection of glycopeptides and glycoproteins that contain asparagine linked carbohydrate chainsincluding those that are core fucosylated in either theorpositionsThis enzyme presents a unique opportunity to engineer a pan specific N glycan detection reagent that will retain the broad specificity of the parent enzyme for all N linked glycansCurrently no pan specific N glycan affinity reagent exists

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

18 SBIR/STTR records share this UEI (2009–2025). Reported award amounts total $14,474,759. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.